| advanced breast cancer (metastatic) | ixabepilone | not classified | versus No demonstrated result for efficacy | 2 trials | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| Sparano, 2010 | ixabepilone (on top capecitabine) vs no ixabepilone | | | overall survival 0.90 [0.78; 1.03] | | Thomas, 2007 | ixabepilone (on top capecitabine) vs no ixabepilone | PFS 0.75 [0.64; 0.88] | | overall survival 0.90 [0.77; 1.05] |
| Trial | Treatments | Patients | Method |
|---|
| Sparano, 2010 | ixabepilone (40 mg/m(2) intravenously on day 1) plus capecitabine (2,000 mg/m(2) orally on days 1 through 14) given every 21 days (n=-9) vs. capecitabine alone (2,500 mg/m(2) on the same schedule) given every 21 days (n=-9) | patients with metastatic breast cancer previously treated with anthracycline and taxanes | open Parallel groups Sample size: -9/-9 Primary endpoint: overall survival FU duration: | | Thomas, 2007 | ixabepilone 40 mg/m(2) intravenously on day 1 of a 21-day cycle plus capecitabine 2,000 mg/m(2) orally on days 1 through 14 of a 21-day cycle (n=752) vs. capecitabine alone 2,500 mg/m(2) on days 1 through 14 of a 21-day cycle (n=0) | patients with metastatic breast cancer progressing after anthracycline and taxane treatment | open Parallel groups Sample size: 752/0 Primary endpoint: progression-free survival FU duration: |
|
